Article

Company files new drug application for topical ED treatment

NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.

NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.

The company said it is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products.

Related Videos
Anna Myers, CNP, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
1 expert in this video
Perry Xu, MD, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
Related Content
WATER III: Aquablation achieves comparable outcomes to laser enucleation for BPH
March 24th 2025

WATER III: Aquablation achieves comparable outcomes to laser enucleation for BPH

Hannah Clarke
The mean change in IPSS from baseline to 3 months was 12.9 in the Aquablation arm vs 13.1 in the LEP arm.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA reports Urgent Device Field Correction notice for CVAC Aspiration System
March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke
Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.
Closeup financial chart with uptrend line candlestick graph in stock market on blue color monitor background | Image Credit: © iamchamp - stock.adobe.com
March 21st 2025

Money Matters: How to cope with market volatility in 2025

Jeff Witz, CFP
"If you determine you can invest in a volatile environment, the best approach is to do so over a period of time," writes Jeff Witz, CFP.
© 2025 MJH Life Sciences

All rights reserved.